Compass 3: A Novel Transition Program to Reduce Disability After Stroke
Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Jul 14, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called Compass 3, is testing a new program to help people recover better after a stroke when they move from hospital rehabilitation back to their home. The study will compare two different types of support: one group will receive education about stroke and how to manage recovery, while the other group will get help making changes to their home environment to make daily life easier and safer.
To join this study, participants need to be 55 years or older and have recently had a stroke. They also should have been able to take care of themselves before the stroke and plan to go home after rehab. Participants must be able to understand the study and agree to take part. Those with serious health problems limiting life expectancy, significant memory or communication issues, or who live in certain types of care facilities won’t be eligible. If accepted, participants will receive one of the two support programs designed to help reduce disability and improve their transition home after stroke recovery. The study is not yet recruiting but aims to provide helpful strategies for stroke survivors and their families.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥55 years at the time of screening
- • Acute stroke diagnosis (IS or ICH) verified by the stroke team or medical record
- • Independent in activities of daily living (ADLs) prior to stroke (premorbid Modified Rankin Scale score ≤2)
- • Plan to discharge to home from an IR
- • Capable of giving informed consent which includes compliance with the requirements and duration of participation as listed in the Informed Consent Form (ICF).
- Exclusion Criteria:
- • Life expectancy \<6 months
- • Cognitive impairment that the participant's stroke team or a research team member believes impairs their ability to provide informed consent or make reasoned choice including the interpretation of the self-rated scales
- • Any communication problem that would prevent study completion
- • Residence in a congregate living facility
- • Not eligible for a therapeutic pass
- • Residence outside of the designated catchment area (specific catchment distance to be determined by each site)
- • Site investigator's judgment that the participant would not be able to complete research procedures or interventions
- • Participation in another research study that in the site investigator's judgment could interfere or conflict with this research study's assessments or interventions
About Washington University School Of Medicine
Washington University School of Medicine is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research, education, and patient care. With a strong emphasis on translating scientific discoveries into practical applications, the institution conducts a diverse array of clinical trials aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. Its collaborative environment fosters partnerships between researchers, clinicians, and community stakeholders, ensuring that the trials not only contribute to scientific knowledge but also address the pressing health needs of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
St. Louis, Missouri, United States
Patients applied
Trial Officials
Susan Stark, PhD
Principal Investigator
Washington University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported